| 22/03 | Jacobio Pharma Announces Clinical Collaboration to Evaluate CD73 Monoclonal Antibody JA.. |  |
| 17/03 | MÄRKTE USA/Schwächer - Anleger gehen vor Wochenende auf Nummer sicher |  |
| 17/03 | MÄRKTE USA/Sorgen um Bankensektor lassen Börsen nicht los | |
| 17/03 | Are we out of the woods now? | |
| 17/03 | MÄRKTE USA/Leichter - Angst vor Finanzkrise schwelt weter | |
| 17/03 | Les valeurs à suivre aujourd'hui à Wall Street - Vendredi 17 mars 2023 |  |
| 17/03 | Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-76.. | |
| 17/03 | Merck & Co : échec d'un essai clinique contre le cancer du poumon | |
| 17/03 | Merck : essai non-concluant dans le cancer du poumon NSCLC | |
| 16/03 | Merck Says Open-Label Arm of Phase 2 Trial of MK-7684A to Treat Lung Cancer Didn't Reac.. | |
| 16/03 | Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-76.. | |
| 16/03 | Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-76.. | |
| 16/03 | Shares Of Inhibikase Therapeutics Stock Decouples From NASDAQ Weakness; Jump 8% Includi.. | |
| 15/03 | In The Queue : AcurX Pharmaceuticals Earnings...Here's What Investors Need To Know Before .. | |
| 14/03 | Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclona.. | |
| 14/03 | Inhibikase Therapeutics Stock Turns Bullish After FDA Lifts Full Clinical Hold For Lead.. | |
| 13/03 | Merck : Wells Fargo dégrade sa recommandation | |
| 13/03 | New entries in the Investor USA portfolio | |
| 13/03 | Nouveaux achats dans le portefeuille Investisseur USA | |
| 13/03 | Merck - KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival versus Chemo.. | |
| 13/03 | Merck & Co.'s Keytruda Extends Patients' Survival in Rare Lung Cancer Study | |
| 10/03 | Merck Says Phase 2/3 Trial of Combination Cancer Therapy Met Primary Endpoint of Overal.. | |
| 10/03 | Merck : succès avec Keytruda dans le cancer de la plèvre | |
| 10/03 | KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Ver.. | |
| 10/03 | Merck & Co., Inc. Announces the Phase 2/3 CCTG IND.227/KEYNOTE-483 Trial Evaluating KEY.. | |
| 09/03 | Vaccinex KEYNOTE B-84 Enrollment Reaches Target for Interim Analysis | |
| 08/03 | MÄRKTE USA/Uneinheitlich - Zinspfad ungewiss | |
| 08/03 | MÄRKTE USA/Uneinheitlich - Zinssorgen bleiben präsent | |
| 08/03 | OPKO Health Subsidiary Working With Merck to Develop Epstein-Barr Virus Vaccine Candida.. | |
| 08/03 | OPKO Health Shares Jump on Licensing Deal With Merck | |
| 08/03 | Sociétés Cotées : GmbH, NV, KGaA, Plc, SpA, Oyj, SGPS... de quoi parle-t.. | |
| 08/03 | Merck & Co, OPKO Health's ModeX to Collaborate on Epstein-Barr Virus Vaccine Candidate | |
| 08/03 | Merck to Present at the Barclays 2023 Global Healthcare Conference | |
| 07/03 | US FDA Approves Intramuscular Administration for Merck's MMRV Family of Vaccines, M-M-R.. | |
| 06/03 | Factory Orders Report Helps Drive Equities Mostly Higher | |
| 06/03 | Merck's Phase 2b Study of MK-0616 Showed Significant Reduction of Bad Cholesterol in Ad.. | |
| 06/03 | Merck's MK-0616 Cuts LDL-C in Hypercholesterolemia in Phase 2b Study | |
| 06/03 | Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Wal.. | |
| 06/03 | Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C i.. | |
| 06/03 | Merck Announces Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Mi.. | |
| 06/03 | Merck Announces MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced.. | |
| 06/03 | Merck : Jefferies initie la couverture à l'achat | |
| 06/03 | ANALYSEN DES TAGES von Dow Jones Newswires (06.03.2023) | |
| 06/03 | This is it | |
| 06/03 | Merck's MMRV Vaccine Family Granted FDA-Approval for Intramuscular Injection | |
| 06/03 | Merck : nouvelle voie d'administration pour des vaccins | |
| 06/03 | Us Fda Approves Intramuscular Admini : M-M-RII (Measles, Mumps, and Rubella Virus Vaccine .. | |
| 06/03 | US FDA Approves Intramuscular Administration for Me.. | |
| 06/03 | RenovoRx, Inc. Full-year 2022 Results Provide Clues Supporting A Near-Term Catalyst-Fue.. | |
| 06/03 | Analyst recommendations: Eli Lilly, Haleon, KB Home, Merck, Pfiz.. | |
| 02/03 | Merck, AstraZeneca Say US FDA's Panel to Review Cancer Drug Lynparza on April 28 | |
| 02/03 | US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo | |
| 02/03 | Merck : rencontre prévue avec un comité de la FDA | |
| 02/03 | Indices: Dow Jones lags | |
| 02/03 | AstraZeneca, Merck & Co.'s Supplemental New Drug Application for Lynparza up for Review.. | |
| 02/03 | Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) fo.. | |
| 02/03 | Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA®? (Olaparib) f.. | |
| 02/03 | RenovoRx, Inc. Shares Surge 117% YTD As Multiple Catalysts Come Into Focus ($RNXT) | |
| 02/03 | Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival i.. | |
| 01/03 | Global markets live: HP, Kohl's, Lowe's, BP, Rivian... | |
| 01/03 | Merck's Phase 3 Study of Keytruda in Non-Small Cell Lung Cancer Meets One Primary Endpo.. | |
| 01/03 | Merck : Phase 3 Keytruda Study Hits Key Goal in Non-Small Cell Lung Cancer | |
| 01/03 | Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (.. | |
| 01/03 | RenovoRx, Inc. Shares Rally As RenovoTAMP Cancer Treatment Platform Continues To Attrac.. | |
| 01/03 | Indices : Le Dow Jones à la traîne | |
| 01/03 | La Chine se re-re-re-réveille ? | |
| 01/03 | En Direct des Marchés : BNP Paribas, Eurofins, Airbus, Euronext, A.. | |
| 28/02 | Merck Discontinues Phase 3 Trial of Combination Therapy With Keytruda to Treat Prostate.. | |
| 28/02 | February ends with uncertainty | |
| 28/02 | Les valeurs à suivre aujourd'hui à Wall Street - Mardi 28 février 2023 | |
| 28/02 | Merck annonce l'arrêt d'un essai clinique après des résultats négatifs sur le Keytruda | |
| 28/02 | Merck : deux échecs en phase 3 pour le Keytruda | |
| 28/02 | Merck & Co Halts Keytruda Phase 3 Trial For Prostate Cancer; Lung Cancer Trial Fails to.. | |
| 28/02 | Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789 | |
| 28/02 | Merck Provides Update on Phase 3 Trials Keynote-641 and Keynote-789 | |
| 27/02 | European Medicines Agency to Reexamine Recommendation for Merck's Lagevrio Pill to Trea.. | |
| 27/02 | 'WSJ': Pfizer an milliardenschwerer Übernahme von Seagen interessiert | |
| 24/02 | MERCK & CO., INC. Management's Discussion and Analysis of Financial Condition and Resu.. | |
| 24/02 | European Committee : Regulators should deny Merck's Lagevrio | |
| 24/02 | Merck : avis négatif en Europe pour le comprimé anti-Covid | |
| 24/02 | Merck, Ridgeback Say EU Regulator Panel Recommends Refusal of Lagevrio's Marketing Auth.. | |
| 24/02 | Merck & Co, Ridgeback to Appeal EU Panel's Recommendation Against COVID-19 Pill for Adu.. | |
| 24/02 | Merck: CHMP Recommends Against OK of Lagevrio for Certain Adults With Covid-19 | |
| 24/02 | Merck : avis négatif du CHMP de l'EMA sur Lagevrio | |
| 24/02 | Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVR.. | |
| 24/02 | Merck and Ridgeback Biotherapeutics Provide Update on EU Marketing Authorization Applic.. | |
| 24/02 | Un an après... | |
| 24/02 | En Direct des Marchés : Saint-Gobain, Valeo, Fnac, Amadeus, Holcim.. | |
| 23/02 | Sliding vaccine sales, new costs, squeeze Moderna 4Q profit | |
| 23/02 | Merck's Request for New Patents for Cancer Drug Keytruda Should be 'Scrutinized', US La.. | |
| 23/02 | Moderna, Merck Granted FDA Breakthrough Designation for Combination Melanoma Therapy | |
| 23/02 | MÄRKTE USA/Im Plus erwartet - Technologiewerte von Nvidia beflügelt | |
| 23/02 | Merck : la FDA accorde un statut de 'breakthrough therapy' | |
| 23/02 | Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer .. | |
| 23/02 | Moderna, Merck & Co.'s Skin Cancer Combo Wins US FDA's Breakthrough Therapy Tag | |
| 22/02 | Merck : Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Ca.. | |
| 22/02 | Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalised mRNA Cancer .. | |
| 22/02 | Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO for Post-exposure.. | |
| 22/02 | Merck : nouveau programme clinique de phase 3 contre le VIH | |
| 22/02 | Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily I.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Reporte
